Teva Concludes Enrollment for Schizophrenia Drug Trial
Teva completes enrollment for Phase 3 trial of mdc-TJK, a potential treatment for schizophrenia. Results expected in 2024. #schizophrenia #clinicaltrials
- Latest
- Trending
Teva completes enrollment for Phase 3 trial of mdc-TJK, a potential treatment for schizophrenia. Results expected in 2024. #schizophrenia #clinicaltrials
The struggles of consumer startups in the venture downturn and the potential of AI to revive the industry. Analytical tone. ...
MSI Claw, the new gaming handheld, features Intel's Core Ultra CPUs, setting it apart from competition. With unique AI-powered features ...
Beware of red flags in loan applications, warns Zerodha founder Nithin Kamath. High interest rates and hidden charges are key ...
Universal Page launches "NFT 2.0" platform on LUKSO blockchain, revolutionizing digital ownership and supporting advanced NFT standards. Karl Lagerfeld and ...
Kering's venture arm joins funding round for biomaterials start-up Mogu, highlighting the fashion industry's growing interest in sustainable materials. #Kering ...
HubSpot Ventures backs doola to support global entrepreneurs, allowing them to easily set up businesses in the US and focus ...
Blazesoft partners with Print Studios, Max Win Gaming, and 4ThePlayer to expand their game collection and enhance the gaming experience ...
Kost Capital, a new European foodtech-focused VC fund, has completed the first close of its €25m fund as it aims ...
Introducing the new Asus ROG Phone 8: a sleek gaming smartphone with AI features and improved durability. Find out more ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.